Evidence map›Paper›PMID 34869418›Full record

ArticleFrontiers in medicine2021

Deciphering CHFR Role in Pancreatic Ductal Adenocarcinoma.

Iranzu González-Borja, Emilia Alors-Pérez, Irene Amat, Laura Alonso, Cristina Viyuela-García, Saioa Goñi, José C Reyes, María Ceballos-Chávez, Irene Hernández-García, Marina E Sánchez-Frías and 9 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 51% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 8 institutions in 1 country.

Iranzu González-BorjaOncobionaTras Lab, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Emilia Alors-PérezHormones and Cancer Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Irene AmatPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Laura AlonsoPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Cristina Viyuela-GarcíaHormones and Cancer Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Saioa GoñiOncobionaTras Lab, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
José C ReyesCentro Andaluz de Biología Molecular y Medicina Regenerativa, Consejo Superior de Investigaciones Científicas-Universidad de Sevilla-Universidad Pablo de Olavide, Seville, Spain.
María Ceballos-ChávezCentro Andaluz de Biología Molecular y Medicina Regenerativa, Consejo Superior de Investigaciones Científicas-Universidad de Sevilla-Universidad Pablo de Olavide, Seville, Spain.
Irene Hernández-GarcíaMedical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Marina E Sánchez-FríasHormones and Cancer Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Enrique SantamaríaProteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Socorro RazquinPathology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Álvaro Arjona-SánchezHormones and Cancer Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Virginia ArrazubiMedical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Jairo Pérez-SanzOncobionaTras Lab, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Ruth VeraMedical Oncology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
Joaquín Fernández-IrigoyenProteomics Platform, Clinical Neuroproteomics Unit, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Justo P CastañoHormones and Cancer Group, Maimonides Institute for Biomedical Research of Cordoba (IMIBIC), Córdoba, Spain.
Antonio ViúdezOncobionaTras Lab, Navarrabiomed, Complejo Hospitalario de Navarra, Universidad Pública de Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
Complejo Hospitalario de Navarra · ESHospital Universitario Reina Sofía · ESNavarrabiomed · ESConsejo Superior de Investigaciones Científicas · ESInstituto Maimónides de Investigación Biomédica de Córdoba · ESNavarre Institute of Health Research · ESUniversidad de Sevilla · ESUniversidad Publica de Navarra · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Checkpoint with forkhead-associated and ring finger domains (

Indexed as

checkpoint with forkhead and ring finger domains (CHFR)DNA methylationimmunohistochemistry (IHC)methylationpancreatic ductal adenocarcinoma (PDAC)

Identifiers

PMID34869418
PMCPMC8639583
OpenAlexW3216842538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.